<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309855</url>
  </required_header>
  <id_info>
    <org_study_id>319-03</org_study_id>
    <nct_id>NCT00309855</nct_id>
  </id_info>
  <brief_title>Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men</brief_title>
  <official_title>Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      This study is being done to understand how testosterone, the major male sex hormone, controls
      the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone,
      which controls sugar; fat and protein use in the body and maintains muscle strength and bone
      calcium content. Both testosterone and GH decline in older men. The age-related fall in these
      hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle
      wasting and impaired sexual function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Repletion of testosterone in older men drives pulsatile GH secretion via conjoint
      facilitation of feedforward by the primary secretagogues GHRH and GHRP and repression of
      feedback by the dominant inhibitor, somatostatin; and, in corollary, testosterone acts via
      aromatization to estradiol and/or reduction to 5 alpha-dihydrotestosterone
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth Hormone concentration after injections</measure>
    <time_frame>24 days</time_frame>
    <description>GH will be measured 4 different times mornings within 16-21 days following the first testosterone injection (day 1).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Double Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone IM and oral placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IM injections weekly x three injections and oral placebo once daily x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone and Oral Anastrozole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IM injections weekly x 3 injections and oral daily x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone and Dutasteride</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IM injections weekly x 3 injections and oral once daily x 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>im and orally</description>
    <arm_group_label>Double Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>injections</description>
    <arm_group_label>Testosterone IM and oral placebo</arm_group_label>
    <arm_group_label>Testosterone and Oral Anastrozole</arm_group_label>
    <arm_group_label>Testosterone and Dutasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrazole</intervention_name>
    <description>orally x 21 days</description>
    <arm_group_label>Testosterone and Oral Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>orally x 21 days</description>
    <arm_group_label>Testosterone and Dutasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men between the ages of 50 and 80;

          -  normal weight (within 30% of ideal body weight defined by New York Metropolitan Life
             tables); and

          -  normal hematocrit (greater than 38%);

          -  community dwelling; and

          -  voluntarily consenting

        Exclusion Criteria:

          -  recent use of psychotropic or neuroactive drugs (within five biological half-live);

          -  obesity (outside weight range above);

          -  anemia (hematocrit &lt; 38%);

          -  drug or alcohol abuse, psychosis, depression, mania or severe anxiety;

          -  acute or chronic organ-system disease;

          -  endocrinopathy, other than primary thyroidal failure receiving replacement;

          -  nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days
             of admission);

          -  acute weight change (loss or gain of &gt; 2 kg in 6 weeks);

          -  allergy to administered compounds; and

          -  unwillingness to provide written informed consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes D. Veldhuis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <name_title>Johannes D. Veldhuis, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

